A Market Survey of Amlodipine (Antihypertensive) in Moradabad City
Abstract
A market survey of Amlodipine (Antihypertensive drug) was conducted at several medical shops in Moradabad City. The various brands of Amlodipine are Citanil-T, Amlokind, Omletime, Amodep, Angicam, Lupidip, Amlogen,Amlip etc. are available in selected areas. The Amlokind is more prescribed by doctors. The highest selling brand of Amlodipine is Amlokind. According to medical survey it has been shown that Amlokind (Mankind Pharmaceuticals Pvt Ltd.) is highest selling brand in Moradabad city. Amlodipine is good Antihypertensive drug.
Keywords:
Amlodipine, Amlokind, Antihypertensive, Citanil-T, Market survey.
References
1.Lackland DT, Weber MA. Global burden of cardiovascular disease and stroke: hypertension at the core. The Canadian journal of cardiology. 2015; 31 (5): 569–71.
2.Mendis S, Puska P, Norrving B. (2011). Global atlas on cardiovascular disease prevention and control (PDF) (1st ed.). Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. p. 38.
3.Poulter NR, Prabhakaran D, Caulfield M. "Hypertension.". Lancet (London, England). 2015; 386 (9995) :801–12.
4.Carretero OA, Oparil S. "Essential hypertension. Part I: definition and etiology". Circulation. 2000; 101 (3) : 329–35
5.Luma GB, Spiotta RT. "Hypertension in children and adolescents". Am Fam Physician. 2006; 73 (9): 1558–68.
6.Kario K. "Orthostatic hypertension: a measure of blood pressure variation for predicting cardiovascular risk. Circulation Journal. 2009; 73 (6) :1002–07.
7.Rodriguez MA, Kumar SK, De Caro M. "Hypertensive crisis". Cardiology in Review. 2010; 18 (2):102–07.
8.Marik PE, Varon J. "Hypertensive crises: challenges and management". Chest. 2007; 131 (6): 1949–62.
9.Palatini P, Julius S. "The role of cardiac autonomic function in hypertension and cardiovascular disease". Curr. Hypertens. Rep. 2009; 11 (3) : 199–205.
10.National Clinical Guidance Centre (August 2011). "7 Diagnosis of Hypertension, 7.5 Link from evidence to recommendations". Hypertension (NICE CG 127) (PDF). National Institute for Health and Clinical Excellence. p. 102. Retrieved 22 December 2011
11.Coca A. "Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers)". Clinical Drug Investigation.2008; 28 (4): 211–20.
12.High blood pressure (hypertension) - Uses for ACE inhibitors". Mayo Clinic. Retrieved 2016-07-27. Page updated: June 29, 2016
13.Levy BI. "How to explain the differences between renin angiotensin system modulators". Am. J. Hypertens. 2005; 18 (9 Pt 2): 134S–141S.
14.Levy BI. "Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system". Circulation. 2004; 109 (1) : 8–13.
15.James PA. " Evidence-Based Guideline for the Management of High Blood Pressure in Adults". JAMA. 2014; 311 (5): 507–20.
16.Wang TJ, Ausiello JC, Stafford RS. "Trends in Antihypertensive Drug Advertising, 1985–1996". Circulation. 1999; 99 (15): 2055–2057.
17.Lindholm LH, Carlberg B, Samuelsson O. "Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis". Lancet. 2005; 366 (9496): 1545–53.
2.Mendis S, Puska P, Norrving B. (2011). Global atlas on cardiovascular disease prevention and control (PDF) (1st ed.). Geneva: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. p. 38.
3.Poulter NR, Prabhakaran D, Caulfield M. "Hypertension.". Lancet (London, England). 2015; 386 (9995) :801–12.
4.Carretero OA, Oparil S. "Essential hypertension. Part I: definition and etiology". Circulation. 2000; 101 (3) : 329–35
5.Luma GB, Spiotta RT. "Hypertension in children and adolescents". Am Fam Physician. 2006; 73 (9): 1558–68.
6.Kario K. "Orthostatic hypertension: a measure of blood pressure variation for predicting cardiovascular risk. Circulation Journal. 2009; 73 (6) :1002–07.
7.Rodriguez MA, Kumar SK, De Caro M. "Hypertensive crisis". Cardiology in Review. 2010; 18 (2):102–07.
8.Marik PE, Varon J. "Hypertensive crises: challenges and management". Chest. 2007; 131 (6): 1949–62.
9.Palatini P, Julius S. "The role of cardiac autonomic function in hypertension and cardiovascular disease". Curr. Hypertens. Rep. 2009; 11 (3) : 199–205.
10.National Clinical Guidance Centre (August 2011). "7 Diagnosis of Hypertension, 7.5 Link from evidence to recommendations". Hypertension (NICE CG 127) (PDF). National Institute for Health and Clinical Excellence. p. 102. Retrieved 22 December 2011
11.Coca A. "Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers)". Clinical Drug Investigation.2008; 28 (4): 211–20.
12.High blood pressure (hypertension) - Uses for ACE inhibitors". Mayo Clinic. Retrieved 2016-07-27. Page updated: June 29, 2016
13.Levy BI. "How to explain the differences between renin angiotensin system modulators". Am. J. Hypertens. 2005; 18 (9 Pt 2): 134S–141S.
14.Levy BI. "Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system". Circulation. 2004; 109 (1) : 8–13.
15.James PA. " Evidence-Based Guideline for the Management of High Blood Pressure in Adults". JAMA. 2014; 311 (5): 507–20.
16.Wang TJ, Ausiello JC, Stafford RS. "Trends in Antihypertensive Drug Advertising, 1985–1996". Circulation. 1999; 99 (15): 2055–2057.
17.Lindholm LH, Carlberg B, Samuelsson O. "Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis". Lancet. 2005; 366 (9496): 1545–53.
Statistics
351 Views | 380 Downloads
How to Cite
Jahan, S., and J. K. Sahu. “A Market Survey of Amlodipine (Antihypertensive) in Moradabad City”. Current Research in Pharmaceutical Sciences, Vol. 7, no. 1, May 2017, pp. 30-32, doi:10.24092/CRPS.2017.070105.
Issue
Section
Research Articles
.